

# Conference Agenda

## TUESDAY, MARCH 26

5:30 pm Registration and Welcome Reception – Mays West Lobby

**A Celebration of the 50th anniversary of screening for Hereditary Medullary Thyroid Cancer**

## WEDNESDAY, MARCH 27

7:00 am Registration and Continental Breakfast

8:00 **Welcome and Opening Remarks**

### PANCREATIC NEUROENDOCRINE TUMORS

- 8:30 **State of the Science in Pancreatic Neuroendocrine Tumors**  
Daniel Halperin, MD
- 8:50 **Emerging Therapies and Epigenetics**  
Kate Lines, PhD
- 9:10 **Menin and Telomeres in Pancreatic Neuroendocrine Tumors**  
Christopher M. Heaphy, PhD
- 9:30 **Observational Studies of Tumor Growth**  
Samira Sadowski, MD
- 9:50 **Perioperative Clinical Trials**  
Matthew HG Katz, MD
- 10:10 **Poster Preview Presentations**  
- 3 at 5 minutes each
- 10:25 Break/Poster Viewing
- 11:10 Plenary Session: Common Failures in Rare Diseases  
**Moderator:** Steven Sherman, MD
- 12:15 Lunch (provided)- Working Lunch in Workshop groups
- 12:30 pm – 2:30 **Disease Site Working Groups** (choose one)
- Medullary Thyroid Cancer
  - Parathyroid Cancer
  - Pancreatic Neuroendocrine Tumor (PNET)
  - Malignant Pheo/PGL
- 2:30 Break

### MEDULLARY THYROID CANCER

- 2:45 **Emerging Therapies In MTC**  
**RET Inhibitor LOXO-292**  
Lori J. Wirth, MD
- RET Inhibitor BLU-667**  
Mimi I. Hu, MD
- Future Trial Development for MTC**  
Vivek Subbiah, MD

3:30 **Transcriptional Targeting of OncoGene Addiction in MTC**  
Matthew D. Ringel, MD

3:50 **Lessons Learned From TCGA and Other Large Scale Genomics Programs**  
Kenna Shaw, PhD

4:10 **Closing Remarks**

4:15 pm Adjourn

## THURSDAY, MARCH 28

7:00 am Registration and Continental Breakfast

7:30 Breakfast Talk - Hereditary Gastrointestinal Neuroendocrine Tumors (optional, non-CME)  
*Sponsored by Lexicon*

8:00 **Welcome and Opening Remarks**

### MALIGNANT PHEOCHROMOCYTOMA AND PARAGANGLIOMA

- 8:10 **State of the Science in Malignant Pheochromocytoma and Paraganglioma**  
Eric Baudin, MD, PhD
- 8:30 **Radiopharmaceuticals, Tyrosine Kinase Inhibitors and Immunotherapy for Patients with Malignant Pheochromocytoma and Paraganglioma**  
Camilo Jimenez, MD
- 8:50 **Pseudohypoxia as a Therapeutic Target: Lessons from Clusters One and Two**  
Patricia L. Dahia, MD, PhD
- 9:10 **Epigenetic Characteristics of Paraganglioma Syndrome Type 4**  
Mercedes Robledo, PhD
- 9:30 **Enabling Replicative Immortality in Pheochromocytoma and Paraganglioma**  
Anne-Paule Gimenez-Roqueplo, MD, PhD
- 9:50 Break/Poster Viewing
- 10:00 **Plenary Session: Immune Checkpoint Blockade in Cancer Therapy: New Insights, Opportunities and Prospects for Cures**  
James Allison, PhD
- 11:00 **Poster Preview Presentations**  
- 3 at 5 minutes each
- 11:15 Break/Poster Viewing
- 11:45 Lunch (provided)- Working Lunch in Workshop groups

- 12:00 – 2:00 pm **Disease Site Working Groups** (choose one)
- Medullary Thyroid Cancer
  - Parathyroid Cancer
  - Pancreatic Neuroendocrine Tumor (PNET)
  - Malignant Pheo/PGL
- 2:00 Break/Poster Viewing

## PARATHYROID CANCERS

- 2:15 **Genetic Syndromes of PHPT and Parathyroid Cancer**  
Maria-Luisa Brandi, MD
- 2:35 **Genetic and Molecular Alterations in Parathyroid Cancer**  
Andrew Arnold, MD
- 2:55 **CDC73**
- 3:15 **The Role of Local Therapies in Parathyroid Cancer: Surgery and Radiotherapy**  
Nancy Perrier, MD
- 3:35 **Targeted Therapies and Trials in Parathyroid Cancer**  
Naifa Busaidy, MD
- 3:55 **Closing Remarks**
- 4:00 pm Adjourn
- 6:30 pm Dinner at Space Center Houston

## FRIDAY, MARCH 29

- 7:00 am Registration and Continental Breakfast
- 8:00 **Welcome and Opening Remarks**

## PITUITARY, ADRENAL CORTEX AND ADRENOCORTICAL TUMORS

- 8:10 **Aggressive Pituitary Tumors: An Update on Pathologic Features and Genomics**  
Gérald Raverot, MD, PhD

- 8:25 **What is New in Familial Isolated Pituitary Adenoma?**  
Albert Beckers, MD, PhD
- 8:40 **X-LAG: An Update**  
Constantine Stratakis, MD, DMSci
- 8:55 **Adrenocortical Tumors: Novel Insights into Pathogenesis of Malignant Adrenocortical Tumors**  
Tobias Else, MD
- 9:10 **Benign Adrenocortical Tumors**  
Jérôme Bertherat, MD, PhD
- 9:25 **VHL as a Paradigm for the Simultaneous Treatment of Multiple Hereditary Tumors**  
Eric Jonasch, MD
- 9:40 **VHL and Pancreatic NETs: An Update**  
Electron Kebebew, MD
- 10:30 Break/Poster Viewing
- 10:45 **Summary of Working Groups**
- 12:00 pm Adjourn

The University of Texas MD Anderson Cancer Center has implemented a process whereby everyone who is in a position to control the content of an educational activity must disclose all relevant financial relationships with any commercial interest that could potentially affect the information presented. MD Anderson also requires that all faculty disclose any unlabeled use or investigational use (not yet approved for any purpose) of pharmaceutical and medical device products. Specific disclosure will be made to the participants prior to the educational activity.

Agendas are subject to change because we are always striving to improve the quality of your educational experience. MD Anderson may substitute faculty with comparable expertise on rare occasions necessitated by illness, schedule conflicts, and so forth.

Photographing, audio taping and videotaping are prohibited.

The University of Texas MD Anderson Cancer Center does not endorse the commercial products, equipment, or services presented by program supporters/exhibitors.

Please let us know what specific topics, issues or questions you wish to see addressed or emphasized in this activity. Fax or e-mail CME/Conference Management. All responses will be forwarded to the Program Chairs for consideration.